

## PRESS RELEASE

## Metropolis Healthcare reports 13.1% growth, higher than industry average.

~Achieves INR 313.4 crores in revenue for Q1 FY25~

Revenue from  
Operations

INR 313.4 Cr



13.1% Y-o-Y

EBITDA

INR 78.2 Cr (25.0%)



21.2% Y-o-Y

PAT

INR 38.1 Cr (12.2%)



31.3% Y-o-Y

**Mumbai, August 10<sup>th</sup>, 2024:** Metropolis Healthcare Limited (NSE: METROPOLIS | BSE: 542650), one of India's leading and reputed diagnostic chains, known for its commitment to quality and scientific excellence, today announced its unaudited consolidated financial results for the quarter ended June 30, 2024.

### Q1FY25 Key Financial Highlights

- **Revenue from Operations** stood at INR 313.4 crores, a growth of 13.1% Y-o-Y basis, well within our guided range of 13-15%.
- **Growth in patient volumes and test volumes** stood at 7% and 10%, respectively for the quarter. Increase in Revenue Per Patient by 6%.
- **Reported EBITDA** stood at INR 78.2 crores, with a growth of 21.2% Y-o-Y.
- **Profit after Tax (PAT)** stood at INR 38.1 crores with a growth of 31.3% Y-o-Y, margins at 12.2%, up from 10.5% for Q1FY24, up by 170 bps Y-o-Y.

"I am pleased to share that we have made considerable progress in the first quarter of FY 2025 with 13.1% growth, which is higher than the industry average. We have consistently achieved high growth in patient volume over the last several quarters and remain optimistic about maintaining this momentum. Our TruHealth (Wellness and Bundling) segment grew by 28% this quarter, which has helped us move the customers up the value chain, resulting in an increase in revenue per patient. We are confident that network expansion, increased footfalls, and a shift in test mix will continue to help us achieve our desired growth".~  
**Ameera Shah, Executive Chairperson and Whole-time Director, Metropolis Healthcare Limited.**

"Our EBITDA and PAT growth have outpaced revenue growth, driven by our focus on TruHealth wellness and bundling packages, Specialty segments, network expansion, and operational efficiencies. B2C revenue grew by 18.4%, contributing 54% of our total revenues. Our network expansion has driven a 18% revenue increase, particularly from Tier III markets, which now account for over 23% of our total revenues. We are present in over 650 towns across India and will continue to focus on growth in B2C, B2B channels, and Tier II and III towns. Looking ahead, we will leverage our brand strength, digital and AI initiatives, talented team, and trusted partnerships to drive aggressive expansion and sustainable growth, creating value for our shareholders."~  
**Surendran Chemmenkotil, Chief Executive Officer, Metropolis Healthcare Limited.**

In INR Crs.	Q1FY25	Q1FY24	Y-o-Y (%)
Revenue from Operations	313.4	277.1	13.1%
EBIDTA (before CSR & ESOP)	80.5	67.0	20.2%
Reported EBITDA	78.2	64.5	21.2%
Reported EBITDA Margins	25.0%	23.3%	170 bps
Profit After Tax	38.1	29.0	31.3%
PAT Margin (%)	12.2%	10.5%	170 bps

\*\*\*\*\*

**About Metropolis:** Established in 1981, Metropolis Healthcare Limited is a leading diagnostics company in India, with a widespread presence in 22 states, 3 Union Territories and over 650 towns. Metropolis touches millions of lives each year by providing actionable health insights to patients and doctors. Metropolis offers a comprehensive range of more than 4,000 plus tests and profiles, including advanced tests for the diagnosis of cancer, neurological disorders, infectious diseases, and various genetic abnormalities.

The company is empowered with a robust network of 204 labs, 4,216 service centers and over 10,000 touch points. Metropolis' commitment to quality and accuracy in each test is reinforced by its consistent CAP proficiency score of more than 98% over the past decade, placing it among the top 1% laboratories worldwide for quality assurance. The Metropolis philosophy rests on the pillars of technological superiority, a warm, patient centric approach and reliable diagnostic reports. For more information, please visit [www.metropolisindia.com](http://www.metropolisindia.com) or click on [Twitter](#), [Facebook](#), or [LinkedIn](#)

### **Safe harbor statement**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

**For further details please contact:**

**Company: Metropolis Healthcare Ltd.**

CIN -L73100MH2000PLC192798

Mr. Jeyasingh Balakrishnan – Head - Corporate Communications

[jeyasingh.b@metropolisindia.com](mailto:jeyasingh.b@metropolisindia.com)

[www.metropolisindia.com](http://www.metropolisindia.com)

**Investor Relations Advisors: Strategic Growth Advisors Pvt. Ltd.**

CIN: U74140MH2010PTC204285

Mr. Shogun Jain / Mr. Sagar Shroff

+91 77383 77756 / +91 98205 19303

[shogun.jain@sgapl.net](mailto:shogun.jain@sgapl.net) / [sagar.shroff@sgapl.net](mailto:sagar.shroff@sgapl.net)